ADHFE1 (Alcohol Dehydrogenase Iron Containing 1)

Drug sensitivity analysis revealed GW.441756, imatinib, and WH.4.023 were more effective in the low-risk group, with varying sensitivities to other drugs in the high-risk group. The qRT-PCR, WB, and IHC results matched the bioinformatics analysis, showing upregulated ATP7B expression in BRCA, indicating the high prognostic potential of the identified genes. ADME-related prognostic genes (GSTM2, ADHFE1, ALDH2, NOS1, ATP7B, and ALDH3A1) are implicated in BRCA pathogenesis, suggesting new therapeutic strategies for BRCA treatment.

Our findings further suggest that these hub genes may serve dual purposes: as indicators of early viral infection, including COVID-19 and related viral illnesses, and as potential predictors of cardiovascular disease (CVD) onset following COVID-19 infection. This work strongly urges health policymakers to implement screening for COVID-19 complications, especially CVDs, in the general public.

Finally, knockdown of the SOD2 gene suppressed tumor cell metabolism, proliferation and metastasis. In conclusion, the present study successfully established a prognostic model based on cuproptosis-related mitochondrial genes and developed a nomogram to predict LUAD prognosis with high accuracy, thereby providing improved tools for treatment decision-making and enhancing patient outcomes.

The findings highlight the prognostic significance of ARPS in BC and its potential utility in guiding personalized treatment strategies. Combining ARPS with clinical parameters enhances prognostic accuracy and may help patients with BC make clinical decisions.

Fecal SDC2, ADHFE1, and PPP2R5C gene methylation detection methods can serve as primary screening tools, supplemented by colonoscopy, to effectively detect colorectal cancer and precancerous lesions. This strategy may prove to be an effective approach for conducting large-scale colorectal cancer screening in average-risk populations.

Using integrated DNA methylation analysis, we identified 3 CRC-related biomarkers with remarkable classification performance. These biomarkers can be used to design a practical clinical toolkit for CRC diagnosis assistance and may also serve as candidate biomarkers for further clinical experiments through liquid biopsies.

Serum ADHFE1 served as an indicator for poor prognosis and liver metastasis of gastric cancer. ADHFE1 regulates gastric cancer cell progression, cisplatin resistance, and angiogenesis, suggesting its potential to serve as a therapeutic target.

Multitarget stool DNA testing is highly sensitive and specific for CRC detection in Thai individuals. This testing could represent as a viable non-invasive alternative to colonoscopy especially in settings where colonoscopy is less accessible or less accepted by patients.

The results of this study verified that the methylation levels of SDC2, ADHFE1 and PPP2R5C in stool DNA were significantly increased in CRC patients. Combined detection of SDC2/ADHFE1/PPP2R5C methylation is a potential non-invasive diagnostic method for CRC and precancerous lesion screening.

Compared to a national CRC program implemented in Hubei Province between 2018 and 2019 using fecal immunochemical tests and CRC risk assessment questionnaires, current program showed a lower initial positive rate (4.4% vs. 17.4%), higher PPVs for CRC (1.3% vs. 0.08%) in the age-matched group, and a higher adherence rate for colonoscopy (71.3% vs. 18.2%). Conclusions Preliminary prospective evidence suggested that fecal DNA tests had promising diagnostic yield in population-based CRC screening, outperforming FIT/risk assessment questionnaire-based screening strategy.

We are currently analyzing the associations between the top differentially methylated regions with ancestry informative markers, and the clinicopathological characteristics of disease, to gain a better understanding of the role of DNA methylation marks in this population. This study adds to our current knowledge on epigenetics marks that will ultimately help us address mortality due to this disease in this population.

CRC patients with low-risk scores combined with TMB levels represent a favorable survival. By integrating analyses of methylation and mutation data, it is suggested that DNA methylation patterns combined with TMB serve as a novel potential biomarker for early screening in more high-TMB populations and for evaluating the prognostic effect of CRC patients with ICI therapy.